Kanzen said Tuesday that it has signed an agreement with Corea Therapeutics, a U.S. based bio-venture, to develop a next-generation anticancer immune cell therapy jointly.
|Corea Therapeutics CEO Won Young-wook (left) and Kanzen CEO Park Tae-gyu shake hands after signing the cooperative agreement at the University of Arizona’s College of Medicine on Jan. 11.|
Corea Therapeutics, which specializes in developing of anticancer immune cell therapy drugs, was established by Professors David A. Bull and Won Young-wook of the University of Arizona Medical School.
The company has original technology to attach antibody-drug conjugates (ADC) specifically to the surface of T cells and natural killer (NK) cells. This technique allowed the company to develop a labeled ADC-tagged NK cell with an antibody-drug complex attached to the surface of immune cells.
Cell-medicines using ADC-tagged NK cells consist of antibodies, chemotherapeutic agents, and NK cells.
Among the components of the ADC-tagged NK cell, the ADC is a biopharmaceutical that binds a potent anticancer drug used in chemotherapy to the antibody and can accurately deliver cancer drugs to cancer cells.
When the ADC-tagged NK cell transfers to the cancer tissue, the chemotherapeutic agent attached to the ADC first attacks the cancer cell, and the cancer cell immunized NK cell immunized attacks the cancer cell again to eradicate the cancer cell.
This technique can attached target anticancer drugs to the surface of immune cells such as T cells or NK cells easily and quickly, is superior in safety and convenience compared to existing technologies, and has excellent caution ratio and efficacy. Also, a single administration can have the same chemotherapy and immunotherapy effects, while a customized administration is possible.
<© Korea Biomedical Review, All rights reserved.>